- Home
- TAC vs HAE Comparison
TAC vs HAE Comparison
Compare TAC & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAC
- HAE
- Stock Information
- Founded
- TAC 1909
- HAE 1971
- Country
- TAC Canada
- HAE United States
- Employees
- TAC N/A
- HAE N/A
- Industry
- TAC Electric Utilities: Central
- HAE Medical/Dental Instruments
- Sector
- TAC Utilities
- HAE Health Care
- Exchange
- TAC Nasdaq
- HAE Nasdaq
- Market Cap
- TAC 4.0B
- HAE 3.6B
- IPO Year
- TAC N/A
- HAE 1991
- Fundamental
- Price
- TAC $10.90
- HAE $62.98
- Analyst Decision
- TAC Buy
- HAE Strong Buy
- Analyst Count
- TAC 1
- HAE 9
- Target Price
- TAC $19.50
- HAE $103.56
- AVG Volume (30 Days)
- TAC 2.2M
- HAE 1.4M
- Earning Date
- TAC 02-20-2025
- HAE 02-06-2025
- Dividend Yield
- TAC 1.61%
- HAE N/A
- EPS Growth
- TAC N/A
- HAE 3.20
- EPS
- TAC 0.41
- HAE 2.54
- Revenue
- TAC $1,977,287,259.00
- HAE $1,373,515,000.00
- Revenue This Year
- TAC N/A
- HAE $7.56
- Revenue Next Year
- TAC N/A
- HAE $3.13
- P/E Ratio
- TAC $26.45
- HAE $24.82
- Revenue Growth
- TAC N/A
- HAE 8.14
- 52 Week Low
- TAC $5.94
- HAE $58.80
- 52 Week High
- TAC $14.64
- HAE $97.97
- Technical
- Relative Strength Index (RSI)
- TAC 42.02
- HAE 38.28
- Support Level
- TAC $10.43
- HAE $58.80
- Resistance Level
- TAC $10.84
- HAE $65.15
- Average True Range (ATR)
- TAC 0.40
- HAE 2.76
- MACD
- TAC 0.08
- HAE 0.34
- Stochastic Oscillator
- TAC 45.39
- HAE 32.85
About TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, hydro, wind & solar, Energy Marketing, gas, energy transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.